Wet AMD – HARBOR Trial

Who is the sponsor?
Genentech, Inc.

Who are the patients?
Male or female patients fifty years of age and older with previously untreated, newly diagnosed wet macular degeneration. The participating doctor will evaluate you to determine your eligibility into the study in accordance with the Study Eligibility and Exclusion Criteria.

How long is the trial?
Participants will be monitored for two years. Treatment will be administered on: (1) a monthly basis for two years or (2) on an as needed basis for two years, after an initial three doses.

When did the trial start at our site?
April 2009

What is the enrollment goal for the sponsor?
1100 patients at 95 study centers

Is the enrollment still open?
The study is ongoing but enrollment is closed.

What is this study investigating?
This is a Phase III, Double-Masked, Multicenter, Randomized, Active Treatment-Controlled Study with the following objective: To compare the safety and efficacy of ranibizumab 2.0 mg dose to the commercially available 0.5 mg dose of ranibizumab in patients with wet macular degeneration. The study goal is to determine if the higher dose can result in better visual outcomes over time and if the best possible visual outcomes can be achieved with fewer injections.

How is the treatment administered?
Ranibizumab is administered as an injection into the eye.